Zoetis shares dropped 25.5% following earnings as investors reacted to an unexpectedly weak U.S. companion animal segment marked by demand softness, increased price sensitivity, intensified competitive pressures, and lack of market expansion that together pressured revenue and margins.

• Organic operational revenue was flat overall; U.S. revenue declined 8% while International grew 10%.
• Companion animal segment fell 4% operationally, driven by weaker demand for premium preventative and chronic care products amid softer clinic traffic and higher price sensitivity.
• Key franchises like dermatology and Simparica suffered share loss due to aggressive competitor pricing and prolonged promotional activity, particularly in the U.S.
• Livestock segment delivered 12% organic operational growth, partially offsetting the weakness in companion animal.
• Management anticipates pipeline-driven growth beyond 2027 but near-term results reflect increased exposure to the challenged premium pet care market and cautious spending trends.